- Home
- LPX vs ELVN Comparison
LPX vs ELVN Comparison
Compare LPX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPX | ELVN |
|---|---|---|
| Founded | 1973 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.2B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LPX | ELVN |
|---|---|---|
| Price | $75.39 | $49.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | ★ $87.71 | $74.42 |
| AVG Volume (30 Days) | 1.4M | ★ 1.6M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $2,708,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.55 | N/A |
| P/E Ratio | $72.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $62.18 | $14.79 |
| 52 Week High | $100.34 | $62.32 |
Technical Indicators
Market Signals| Indicator | LPX | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 62.54 |
| Support Level | $74.14 | $44.18 |
| Resistance Level | $77.25 | $52.39 |
| Average True Range (ATR) | 3.16 | 2.15 |
| MACD | 0.41 | 1.03 |
| Stochastic Oscillator | 52.99 | 92.95 |
Price Performance
Historical ComparisonAbout LPX Louisiana-Pacific Corporation
Louisiana-Pacific Corp is an oriented strand board producer and also offers engineered wood siding used in home construction and repair and remodel projects. The Siding business of the company serves different markets with a broad product portfolio of engineered wood siding, trim, soffit, and fascia. The Company operates through three operating segments: Siding, OSB, and LP South America (LPSA). The company generates majority of its revenue from siding segment.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.